Document Detail


Continuous-Flow Left Ventricular Assist Device Therapy in Patients With Preoperative Hepatic Failure: Are We Pushing the Limits Too Far?
MedLine Citation:
PMID:  25345547     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The purpose of this study was to evaluate the effects and outcome of continuous-flow left ventricular assist device (cf-LVAD) therapy in patients with preoperative acute hepatic failure. The study design was a retrospective review of prospectively collected data. Included were 42 patients who underwent cf-LVAD implantation (64.3% HeartMate II, 35.7% HeartWare) between July 2007 and May 2013 with preoperative hepatic failure defined as elevation of greater than or equal to two liver function parameters above twice the upper normal range. Mean patient age was 35 ± 12.5 years, comprising 23.8% females. Dilated cardiomyopathy was present in 92.9% of patients (left ventricular ejection fraction 17.3 ± 5.9%). Mean support duration was 511 ± 512 days (range: 2-1996 days). Mean preoperative laboratory parameters for blood urea nitrogen, serum creatinine, total bilirubin, and alanine aminotransferase were 9.5 ± 5.4 mg/dL, 110.3 ± 42.8 μmol/L, 51.7 ± 38.3 mmol/L, and 242.1 ± 268.6 U/L, respectively. All parameters decreased significantly 1 month postoperatively. The mean preoperative modified Model for Endstage Liver Disease excluding international normalized ratio score was 16.03 ± 5.57, which improved significantly after cf-LVAD implantation to 10.62 ± 5.66 (P < 0.001) at 7 days and 5.83 ± 4.98 (P < 0.001) at 30 days postoperatively. One-year and 5-year survival was 75.9 and 48.1%, respectively. 21.4% of the patients underwent LVAD explantation for myocardial recovery, 16.7% were successfully transplanted, and 7.1% underwent LVAD exchange for device failure over the follow-up period. Patients with preexisting acute hepatic failure are reasonable candidates for cf-LVAD implantation, with excellent rates of recovery and survival, suggesting that cf-LVAD therapy should not be denied to patients merely on grounds of "preoperative elevated liver enzymes/hepatopathy."
Authors:
Alexander Weymann; Nikhil P Patil; Anton Sabashnikov; Phrashant N Mohite; Diana Garcia Saez; Christian Bireta; Thorsten Wahlers; Matthias Karck; Klaus Kallenbach; Arjang Ruhparwar; Javid Fatullayev; Mohamed Amrani; Fabio De Robertis; Toufan Bahrami; Aron-Frederik Popov; Andre R Simon
Related Documents :
21585177 - The role of predictor factors in patients with non hodgkin lymphoma in relation to the ...
11005517 - Semiconstrained total elbow arthroplasty for ankylosed and stiff elbows.
25400507 - Glidescope use improves intubation success rates: an observational study using propensi...
21939937 - Impact of intravascular ultrasound imaging on early and late clinical outcomes followin...
20887927 - Anatomic double-bundle anterior cruciate ligament reconstruction using hamstring tendon...
18401107 - End-growth results of bracing and exercises for adolescent idiopathic scoliosis. prospe...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-27
Journal Detail:
Title:  Artificial organs     Volume:  -     ISSN:  1525-1594     ISO Abbreviation:  Artif Organs     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-10-27     Completed Date:  -     Revised Date:  2014-10-28    
Medline Journal Info:
Nlm Unique ID:  7802778     Medline TA:  Artif Organs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long unidirectional barbed suturing technique with extracorporeal traction in laparoscopic myomectom...
Next Document:  Comparison of segmental multifrequency bioelectrical impedance analysis with dual-energy X-ray absor...